Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
4900 Results for "
Conjugates
" in MedChemExpress (MCE) Product Catalog:
Products (4900)
4900 Results for "Conjugates" in MCE Product Catalog:
Cat. No.: HY-148140C
CAS No.: 9041-35-4
Target:
Research Areas:
Cross-linked dextran G 25, fine is a cross-linked dextran gel chromatography fine (average particle size D50 = 70-90 μm) that possesses multiple separation activities, including molecular sieve effects, weak anion exchange, and aromatic adsorption. Cross-linked dextran G 25, fine weakly exchanges cations through immobilized terminal carboxyl groups and repels anions at low ionic strength. Cross-linked dextran G 25, fine is used for the fractionation of low molecular weight solutes, including peptides, amino acids, nucleotide sugar derivatives, and aromatic compounds .
Cat. No.: HY-187336
CAS No.: 3087291-80-0
Nampt-IN-22 is a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-22 blocks the NAD + salvage synthesis pathway by inhibiting nicotinamide phosphoribosyltransferase (NAMPT). Its tertiary alcohol forms hydrogen bonds with His191 of NAMPT and enhances lysosomal stability via intramolecular hydrogen bonds. As an ADC payload, Nampt-IN-22 exhibits low nanomolar cytotoxicity against tumor cells after conjugation to an anti-CD30 antibody, prolongs survival in a disseminated L540 Hodgkin lymphoma mouse model, and suppresses subcutaneous tumor growth. Nampt-IN-22 can be used in studies related to Hodgkin lymphoma .
Cat. No.: HY-123715
CAS No.: 1983924-20-4
Anticancer agent 255 is a monocarbonylated curcumin-1,2,3-oxazole conjugate with significant anticancer activity. The IC50 values of Anticancer agent 255 in prostate cancer cells PC-3 and DU-145 are 8.8μM and 9.5μM respectively. The IC50 values of Anticancer agent 255 against breast cancer cells MCF-7, MDA-MB-231 and 4T1 are 6μM, 10μM and 6.4μM, showing good anti-cancer activity Effect. Anticancer agent 255 can induce mitochondria-mediated apoptosis in cancer cells and prevent cell cycle progression. Anticancer agent 255 down-regulated the cell proliferation marker PCNA and inhibited the activation of cell survival proteins. Anticancer agent 255 up-regulated the pro-apoptotic protein Bax and down-regulated the anti-apoptotic protein Bcl-2 .
Cat. No.: HY-131027
Purity: 99.87%
Synonyms: JF646, Azide
Cat. No.: HY-174870
Research Areas:
PROTAC ERα Degrader-11 is a selective and intrinsically fluorescent (Ex: 366 nm, Em: 440 nm) ERα PROTAC degrader. PROTAC ERα Degrader-11 shows good antiproliferative activity, selective ERα degradation and imaging capabilities in MCF-7 breast cancer cell lines. PROTAC ERα Degrader-11 induces G2/M phase arrest and induces apoptosis in MCF-7 cells. PROTAC ERα Degrader-11 is well-tolerated up to a dose of 500 mg/ kg with no acute toxicity in athymic nude mice. PROTAC ERα Degrader-11 can be used for the study of breast cancer.(Pink: ERα ligand (HY-167701), Blue: CRBN Ligand (HY-150831), Black: Linker, E3 ligase ligand-linker conjugate (HY-174880)) .
Cat. No.: HY-187243
Synonyms: DMG-PEG1000-Cys-SRNLIDC
Target:
Research Areas:
DMG-PEG1000-LyP-1 (DMG-PEG1000-Cys-SRNLIDC) is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, PEG, and LyP-1 peptide (CGNKRTRGC) (HY-P2526) as the terminal targeting/functional ligand. LyP-1 is a cyclic 9-amino acid peptide that specifically binds to p32/gC1qR protein, which is highly expressed on tumor-associated macrophages, lymphatic endothelial cells, and certain tumor cells. DMG-PEG1000-LyP-1 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against p32/gC1qR protein on the surface of lymphatic vessels, tumor-associated macrophages, and tumor cells.
Cat. No.: HY-187243A
Synonyms: DMG-PEG2000-Cys-SRNLIDC
Target:
Research Areas:
DMG-PEG2000-LyP-1 (DMG-PEG2000-Cys-SRNLIDC) is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, PEG, and LyP-1 peptide (CGNKRTRGC) (HY-P2526) as the terminal targeting/functional ligand. LyP-1 is a cyclic 9-amino acid peptide that specifically binds to p32/gC1qR protein, which is highly expressed on tumor-associated macrophages, lymphatic endothelial cells, and certain tumor cells. DMG-PEG2000-LyP-1 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against p32/gC1qR protein on the surface of lymphatic vessels, tumor-associated macrophages, and tumor cells.
Cat. No.: HY-187243B
Synonyms: DMG-PEG3400-Cys-SRNLIDC
Target:
Research Areas:
DMG-PEG3400-LyP-1 (DMG-PEG3400-Cys-SRNLIDC) is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, PEG, and LyP-1 peptide (CGNKRTRGC) (HY-P2526) as the terminal targeting/functional ligand. LyP-1 is a cyclic 9-amino acid peptide that specifically binds to p32/gC1qR protein, which is highly expressed on tumor-associated macrophages, lymphatic endothelial cells, and certain tumor cells. DMG-PEG3400-LyP-1 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against p32/gC1qR protein on the surface of lymphatic vessels, tumor-associated macrophages, and tumor cells.
Cat. No.: HY-187243C
Synonyms: DMG-PEG5000-Cys-SRNLIDC
Target:
Research Areas:
DMG-PEG5000-LyP-1 (DMG-PEG5000-Cys-SRNLIDC) is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, PEG, and LyP-1 peptide (CGNKRTRGC) (HY-P2526) as the terminal targeting/functional ligand. LyP-1 is a cyclic 9-amino acid peptide that specifically binds to p32/gC1qR protein, which is highly expressed on tumor-associated macrophages, lymphatic endothelial cells, and certain tumor cells. DMG-PEG5000-LyP-1 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against p32/gC1qR protein on the surface of lymphatic vessels, tumor-associated macrophages, and tumor cells.
Cat. No.: HY-187318
Synonyms: DOPE-PEG1000-Cys-SRNLIDC
Target:
Research Areas:
DOPE-PEG1000-LyP-1 (DOPE-PEG1000-Cys-SRNLIDC) is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, PEG, and LyP-1 peptide (CGNKRTRGC) (HY-P2526) as the terminal targeting/functional ligand. LyP-1 is a cyclic 9-amino acid peptide that specifically binds to p32/gC1qR protein, which is highly expressed on tumor-associated macrophages, lymphatic endothelial cells, and certain tumor cells. DOPE-PEG1000-LyP-1 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against p32/gC1qR protein on the surface of lymphatic vessels, tumor-associated macrophages, and tumor cells.
Cat. No.: HY-187318A
Synonyms: DOPE-PEG2000-Cys-SRNLIDC
Target:
Research Areas:
DOPE-PEG2000-LyP-1 (DOPE-PEG2000-Cys-SRNLIDC) is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, PEG, and LyP-1 peptide (CGNKRTRGC) (HY-P2526) as the terminal targeting/functional ligand. LyP-1 is a cyclic 9-amino acid peptide that specifically binds to p32/gC1qR protein, which is highly expressed on tumor-associated macrophages, lymphatic endothelial cells, and certain tumor cells. DOPE-PEG2000-LyP-1 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against p32/gC1qR protein on the surface of lymphatic vessels, tumor-associated macrophages, and tumor cells.
Cat. No.: HY-187318B
Synonyms: DOPE-PEG3400-Cys-SRNLIDC
Target:
Research Areas:
DOPE-PEG3400-LyP-1 (DOPE-PEG3400-Cys-SRNLIDC) is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, PEG, and LyP-1 peptide (CGNKRTRGC) (HY-P2526) as the terminal targeting/functional ligand. LyP-1 is a cyclic 9-amino acid peptide that specifically binds to p32/gC1qR protein, which is highly expressed on tumor-associated macrophages, lymphatic endothelial cells, and certain tumor cells. DOPE-PEG3400-LyP-1 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against p32/gC1qR protein on the surface of lymphatic vessels, tumor-associated macrophages, and tumor cells.
Cat. No.: HY-187318C
Synonyms: DOPE-PEG5000-Cys-SRNLIDC
Target:
Research Areas:
DOPE-PEG5000-LyP-1 (DOPE-PEG5000-Cys-SRNLIDC) is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, PEG, and LyP-1 peptide (CGNKRTRGC) (HY-P2526) as the terminal targeting/functional ligand. LyP-1 is a cyclic 9-amino acid peptide that specifically binds to p32/gC1qR protein, which is highly expressed on tumor-associated macrophages, lymphatic endothelial cells, and certain tumor cells. DOPE-PEG5000-LyP-1 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against p32/gC1qR protein on the surface of lymphatic vessels, tumor-associated macrophages, and tumor cells.
Cat. No.: HY-187361
CAS No.: 3107740-33-7
PROTAC HIV-1 degrader-1 is a HIV-1 capsid (CA) PROTAC degrader, with a DC50 of 3 nM against HIV-1IIIB (MT‑4 cells) and a DC50 of 1.17 nM against HIV-1NL4-3 (MT‑4 cells). PROTAC HIV-1 degrader-1 conjugates HIV-1 capsid (CA) with the VHL E3 ubiquitin ligase, triggering polyubiquitination and proteasome-mediated degradation of CA, as well as competitively inhibiting the binding of host factors CPSF6 and Sec24C to CA. PROTAC HIV-1 degrader-1 degrades CA drug-resistant mutants (N74D, K70R). PROTAC HIV-1 degrader-1 is applicable to research related to HIV-1 infection .
Cat. No.: HY-D2747
CAS No.: 1638784-10-7
Cat. No.: HY-P11698
CAS No.: 476667-31-9
Research Areas:
Cat. No.: HY-P4087
CAS No.: 1417221-06-7
Cat. No.: HY-P4087B
Cat. No.: HY-L050
507 compounds
Protein ubiquitination is an enzymatic post-translational modification in which an ubiquitin protein is attached to a substrate protein. Ubiquitination involves three main steps: activation, conjugation, and ligation, performed by ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin ligases (E3s), respectively. Ubiquitination affects cellular processes such as apoptosis, cell cycle, DNA damage repair, and membrane transportation, etc. by regulating the degradation of proteins (via the proteasome and lysosome), altering the cellular localization of proteins, affecting proteins activity, and promoting or preventing protein-protein interactions. Deregulation of ubiquitin pathway leads to many diseases such as neurodegeneration, cancer, infection and immunity, etc.
MCE offers a unique collection of 507 small molecule modulators with biological activity used for ubiquitination research. Compounds in this library target the key enzymes in ubiquitin pathway. MCE Ubiquitination Compound Library is a useful tool for the research of ubiquitination regulation and the corresponding diseases.
Cat. No.: HY-W998680
CAS No.: 2228857-33-6
Synonyms: 5-FITC-Maleimide
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
